10x Genomics, Inc. has filed a Form 3 with the SEC, indicating a change in ownership by Joseph E. Gilliam, who is now a director of the company. This filing, dated November 6, 2026, is significant as it reflects the ongoing developments within the company and the Laboratory Analytical Instruments sector.

Background

10x Genomics, Inc. operates in the Laboratory Analytical Instruments industry, classified under SIC code 3826. The company is publicly traded under the ticker symbol TXG on the Nasdaq exchange. As a large accelerated filer, 10x Genomics has been active in the market, with several recent filings, including a Form 10-Q and multiple Form 8-K submissions.

What the Filing Says

The SEC filing reveals that Joseph E. Gilliam now holds 31 shares of Class A Common Stock in 10x Genomics, reflecting his role as a director. The filing states, "No Securities Owned" prior to this transaction, indicating this is a new acquisition of shares.

Impact

This change in ownership may affect the governance of 10x Genomics, as Gilliam's position as a director could influence strategic decisions. The filing also highlights the company's ongoing engagement with its stakeholders and compliance with SEC regulations. Additionally, this development may have implications for competitors in the Laboratory Analytical Instruments sector, including Glaukos Corporation, which is mentioned in the context of Gilliam's address.

What's Next

The filing does not say what happens next.